Black Diamond Rg

Clinical‑stage oncology firm Black Diamond Therapeutics develops MasterKey inhibitors for genetically defined tumors, led by Phase 2 BDTX‑1535, an irreversible brain‑penetrant EGFR blocker, with additional RAF and FGFR MasterKeys in early trials.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 24
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
BDTX	Black Diamond Rg Cap: 0.2B \| P/E: 7.6	EQUITY	NMS	USD	US09203E1055	Active	📈